Skip to main content
Premium Trial:

Request an Annual Quote

Ginkgo Bioworks Nabs $70M Investment from Illumina, Others to Build Coronavirus NGS Testing

NEW YORK ─ Ginkgo Bioworks on Thursday announced a $70 million investment from Illumina and current investors General Atlantic and Viking Global Investors to build large-scale sequencing-based coronavirus testing infrastructure.

Boston-based Ginkgo, a synthetic biology firm, said that coupling Illumina's next-generation sequencing technology with Ginkgo's hardware and software for the large-scale automation of biological experiments has the potential to increase COVID-19 testing capacity to unprecedented scale, contributing to the testing volume that many public health experts believe is necessary for slowing the spread of the virus.

Ginkgo is building an epidemic monitoring and diagnostic testing facility in its Boston Seaport labs and is developing processes that use Illumina's NGS technology for large-scale testing, whole-genome sequencing, and environmental monitoring.

It aims to make its NGS-based testing capacity available to help reopen schools and businesses and has already made its current NGS capacity available at no cost to public health departments across the US. Earlier this month, Ginkgo said it was in the process of getting its lab CLIA-certified and had filed a pre-EUA with the US Food and Drug Administration for an NGS-based test.

NGS equipment can read, process, and analyze many DNA and RNA samples in parallel on one machine, enabling tens of thousands of SARS-CoV-2 tests to be run at the same time on equipment the size of a washing machine, Ginkgo noted.

NGS data are also invaluable for public health efforts, such as contact tracing and understanding community spread, and whole-genome-sequencing data provide insights for global research to track the virus and develop therapies and vaccines, the company said.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.